We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Baring Private Equity Asia (BPEA), through its affiliated private equity funds, has agreed to acquire a medical devices company Lumenis for more than $1bn. Lumenis is engaged in
Pfizer has secured the US Food and Drug Administration (FDA) approval for its ABRILADA (adalimumab-afzb), as a biosimilar to AbbVie’s Humira (adalimumab). Adalimumab is a tumour necrosis factor
US-based pharmaceutical firm Dicerna has signed an agreement with Denmark-based Novo Nordisk to discover and develop therapies for the treatment of liver-related cardio-metabolic diseases, using its GalXC RNAi
US-based biopharmaceutical firm Amgen has unveiled new analysis from FOURIER study, designed to evaluate the effectiveness of Repatha (evolocumab) in patients who suffered a myocardial infarction (MI) recently.
AstraZeneca has secured the European Commission (EC) approval for its Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets, used for improving glycaemic control in adults with type-2 diabetes
FUJIFILM Diosynth Biotechnologies (FDB), a partnership between FUJIFILM and Mitsubishi, has announced its plans to expand its gene therapy services by adding dedicated process and analytical development laboratories.
The US Food and Drug Administration (FDA) has accepted AstraZeneca and MSD’s New Drug Application (NDA) and granted Priority Review for selumetinib as a potential new medicine for
UK-based pharmaceutical firm GlaxoSmithKline (GSK) has unveiled positive results from the study of Nucala (mepolizumab) for treating patients with Hypereosinophilic Syndrome (HES). The phase 3 study is a
Integrated healthcare solutions firm Cardinal Health has expanded its partnership with Tata Consultancy Services (TCS) for the transformation of its IT operating model. Under the collaboration, TCS will
Mylan and Pfizer have announced that the name of the new company, to be established by the planned merger of Mylan and Pfizer’s Upjohn, will be Viatris. The